Hemab Therapeutics Holdings, Inc. filed its quarterly report on Form 10-Q with the SEC on November 10, 2026, covering the period ended September 30, 2026, disclosing share count, pipeline status, and company classification as an emerging growth company listed on NASDAQ:COAG.
Key Highlights
- Shares outstanding: As of October 30, 2026, the registrant had 46,730,608 shares of common stock, $0.0001 par value per share, outstanding.
- Company classification: Hemab Therapeutics is designated as a non-accelerated filer, smaller reporting company, and emerging growth company under Rule 12b-2 of the Exchange Act.
- Lead clinical program: The filing references the SOLARA Phase 3 clinical trial of sutacimig in patients with Glanzmann thrombasthenia as an ongoing program.
- Additional pipeline programs: The filing references a Phase 2b trial of sutacimig in Factor VII deficiency and the VELORA Pioneer Phase 1/2 trial of HMB-002 in patients with Von Willebrand Disease.
- Early-stage asset: The filing also references a Phase 1 clinical trial of HMB-003 with timing of initial clinical data cited as a forward-looking item.
- Principal offices: The company is headquartered at 101 Main Street, Suite 1220, Cambridge, Massachusetts 02142.
Hemab Therapeutics Reports Q3 2026 Filing Status and Pipeline Scope
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG), a Delaware-incorporated biopharmaceutical company based in Cambridge, Massachusetts, submitted its quarterly report covering the three- and nine-month periods ended September 30, 2026. According to the filing, the company confirmed it had filed all required reports under the Securities Exchange Act during the preceding 12 months and had submitted all required Interactive Data Files electronically.
The filing identifies the company's lead product candidate as sutacimig, which is being evaluated in the SOLARA Phase 3 clinical trial for patients with Glanzmann thrombasthenia, a rare bleeding disorder. According to the filing, the company also cited a Phase 2b clinical trial of sutacimig in Factor VII deficiency, and Part B of the VELORA Pioneer Phase 1/2 trial of HMB-002 in patients with Von Willebrand Disease, as additional programs for which data timing is discussed as a forward-looking matter. The filing also references HMB-003, which the company disclosed is in a Phase 1 clinical trial.
The filing includes forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act and Section 21E of the Securities Exchange Act of 1934, as amended, covering topics including clinical trial progress, capital requirements, regulatory interactions, and commercialization strategy. The company cautions that "actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make," and directs readers to the Risk Factors section in Item 1A of the report. The company is incorporated in Delaware and carries I.R.S. Employer Identification Number 41-4241952.
What Was Disclosed
Hemab Therapeutics Holdings, Inc. filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 46,730,608 shares outstanding as of October 30, 2026, its emerging growth company status, and the scope of its clinical-stage pipeline including sutacimig, HMB-002, and HMB-003.



Please wait processing your request...